Loading
Life sciences · Journal article
American Journal of Ophthalmology · September 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Endothelial keratoplasty remains the current gold standard for treating corneal endothelial dysfunction, relying on transplantation of cadaveric donor-derived Descemet's membrane with functional corneal endothelial cells (CECs) to restore corneal clarity. However, global shortages of suitable cadaveric donor tissue have accelerated interest in corneal endothelial cell therapy, tissue engineering, and non-surgical, donor-sparing, and potentially donor-independent therapeutic approaches. In this review, we discuss recent advances in corneal endothelial cell therapy, tissue engineering, gene- and RNA-targeted approaches, and pharmacologic therapies aimed at preserving or replacing the corneal endothelium. These modalities span markedly different levels of translational maturity. Cultured donor-derived CEC injection is the most clinically advanced, with regulatory approval and commercial use in Japan and Phase 3 development in the United States. Tissue-engineered endothelial grafts have entered first-in-human evaluation, whereas mitochondrial transfer and extracellular vesicle–based strategies remain preclinical. Molecular and pharmacologic approaches range from Phase 2 evaluation of TCF4-directed transcriptional modulation and clinically studied ROCK inhibitors to preclinical antisense oligonucleotides (ASO) and CRISPR-based strategies. We therefore compare these modalities according to current evidence, translational readiness, scalability, manufacturing requirements, and potential clinical role.